Across the health system | A question to investigate
Better preparation makes room for a better discussion.
A formulary committee needs evidence it can question, not another confident summary that hides the difficult parts. Indication, comparator, relevance and uncertainty all matter to the decision. Our proposed PHARMORIS evaluation concerns the preparation of a traceable evidence brief for an agreed local question. It asks whether the work can become more consistent and less burdensome while preserving specialist appraisal and the committee's authority. The commercial value would have to survive the checking effort, rather than depend on reviewers accepting a draft at face value.
In the conversation.
NEUVIOR and our founder’s perspectives have appeared across science, business and technology publications.
Reporting, commentary, letters and podcast appearances | Read each feature for its format and source.
Respect the decision already made nationally.
NICE's local formulary guidance distinguishes national technology-appraisal recommendations from local evidence work and implementation (NICE, 2014). The proposed task should establish that boundary first. It must not recreate a national appraisal or suggest that software can overturn it. Where local appraisal is appropriate, identify the exact question the committee is entitled and equipped to answer. This avoids spending time on an impressive evidence pack that addresses the wrong decision and clarifies which local expertise needs to review the output.
Choose a fair clinical and organisational comparator.
A brief can be misleading even when each sentence is accurate. It may compare a new option with an outdated pathway, omit relevant service costs or mix populations from different studies. The proposed review would make the comparator and scope explicit before drafting begins. Separate clinical evidence, implementation requirements and local resource assumptions. Show where the available literature cannot answer the local question. That structure gives specialists a way to disagree with the reasoning without having to reconstruct the entire evidence search.
A decision brief should state the population, indication, intervention, relevant comparator and outcomes before presenting the evidence. Add a separate local implementation question: what would change here if the nationally or locally agreed position were introduced? These two layers should remain distinguishable. Evidence supporting a medicine in a study population does not, on its own, establish the staffing, pathway or budget implications of introducing it in a particular organisation.
Keep sources attached to the claims.
Each substantive claim should have a source and enough context for a reviewer to check its meaning. Record the evidence date, population and important limitations in the working brief. Distinguish a reported study finding from the team's interpretation of its local relevance. Do not fill an absent comparison with an invented estimate. A well-designed brief helps the committee locate the uncertainty quickly; a long bibliography alone does not establish that the right evidence has been used or interpreted correctly.
Test a defined preparation task.
A first PHARMORIS evaluation could use public sources and an approved historical or synthetic committee question. Compare the usual preparation approach with a PHARMORIS-supported draft, using the same scope and evidence cut-off. Independent specialists would define the critical facts and omissions before scoring the outputs. The initial task would produce preparation material, not a formulary decision. NICE's digital-health evidence framework can inform planning, but the study design and assurance requirements depend on the actual intended use (NICE, n.d.).
A better brief leaves room for challenge.
An investment case gets stronger when it explains the conditions for repetition. Make the next commitment depend on evidence.
A formulary team needs an evidence brief it can inspect and challenge before a decision. Preparation effort, source relevance and unresolved uncertainty matter more than how confident a summary sounds.
Supports an investable boundary: suitable now, suitable after a defined dependency, unsuitable under present conditions or still unknown.
What would we need to understand?
- Defined committee question
- Relevant evidence and authorised sources
- Current briefing and verification method
- Uncertainty requiring expert interpretation
Constructed decision example | No customer results are shown.
Measure the complete review burden.
Candidate outcomes include important facts accurately represented, unsupported claims, missing relevant evidence, source traceability and total preparation plus correction time. Reviewers should score the quality before considering speed. Include examples where the evidence conflicts, where the comparator is uncertain and where no useful conclusion is possible. Report the conditions under which the draft fails. A successful preparation study would justify a next evaluation step; it would not establish clinical benefit, regulatory status or the validity of every future brief.
Stop before fluency becomes authority.
The evaluation should stop if a draft fabricates a source, misstates a national recommendation or presents an unresolved comparison as settled. Agree tolerances for less critical errors and for the time required to correct them. If the process produces polished prose that reviewers must effectively rewrite, it has not earned adoption. The useful product is a trustworthy preparation aid within an accountable process. That is a demanding commercial standard, and one that makes the eventual proposition more credible to specialist buyers.
Bring a question the committee already recognises.
A medicines-information pharmacist, formulary lead or committee chair can start with one recurring preparation task and the standards a usable brief must meet. We would agree the sources, reviewer roles and comparison before discussing a study. The incentive is tangible: more time for judgement and a clearer account of the evidence behind deliberation. Whether PHARMORIS can support that result is what the proposed evaluation would test, with publication of any findings subject to separate agreement and review.
NEUVIOR Data Analysis
A source.
A question.
A clearer decision.
Useful intelligence keeps its evidence attached.
Our public analysis connects a defined question with named sources, reporting periods and methods. Each source below shows the work available today and the access still needed.
Published-data analysis, research hypotheses and evidence studies are distinct kinds of work. Their meaning should remain clear as the programme grows.
NHS Business Services Authority | Annual
Prescription Cost Analysis
How does activity differ from ingredient-cost concentration?
Analysis availableNHS Business Services Authority | Monthly
English Prescribing Dataset with SNOMED Code
Which product and organisational patterns merit a closer investigation?
Metadata retrievedMedicines and Healthcare products Regulatory Agency | Event-driven; monthly roundup also published
Medicines and device safety communications
Which official communication should a responsible team read next?
Snapshot retrievedNHS Business Services Authority and NHS England | Weekly
Dictionary of medicines and devices
Can the same product identity be followed consistently across sources?
Access reviewSources and further reading
NICE (2014) Developing and updating local formularies, MPG1. Available at: https://www.nice.org.uk/guidance/mpg1/chapter/recommendations (Accessed: 14 October 2026).
NICE (n.d.) Evidence standards framework user guide. Available at: https://www.nice.org.uk/corporate/ecd7/resources/evidence-standards-framework-for-digital-health-technologies-user-guide-9024813901/chapter/how-to-use-the-framework (Accessed: 14 October 2026).
Another useful angle.
- A monitoring task needs an owner, not another reminder.
A task can look complete in one organisation while remaining unresolved in another.
- A formulary decision is the start of the work.
A committee can approve a medicines position while implementation still depends on protocols, communications, ordering, training and responsibilities across organisations.
- Make stewardship review easier to prepare, not easier to bypass.
An antimicrobial stewardship team needs information that supports careful review under real service pressures.